| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
BIMI International Medical Inc. (NASDAQ:BIMI, ", BIMI", ))))), a leading global provider of healthcare services and innovative medical solutions, today announced the formation of a strategic partnership between its subsidiary, Phenix Bio Inc. ("Phenix") and China Duty Free Group ("CDFG"), one of the largest and most influential state-owned duty-free retail enterprises in China.
The Purchase Agreement between Phenix and CDFG, which became effective on August 1, 2023, provides that CDFG will distribute a selection of Phenix's healthcare products across all of its retail stores for a one-year term.
Under the term of the agreement, a selection of Phenix's high-quality dietary supplements will be made available to Chinese consumers through CDFG's extensive network of duty-free retail locations in airports, cruise terminals, and downtown stores. The partnership aims to improve the accessibility of world-class dietary supplements to China's growing population, while further expanding BIMI and Phenix's footprint in the Asian market.
A signing ceremony was held at BIMI's headquarters in New York City where representative from both parties, including BIMI's Chief of Staff, Symington Smith and CDFG executives, attended.
"We are thrilled to partner with China Duty Free Group, a company that shares our commitment to excellence and innovation in the healthcare sector," said Tiewei Song, CEO of BIMI. "This partnership represents a significant opportunity for our company to leverage CDFG's extensive distribution network, while offering Chinese consumers access to our best-in-class products and services."
Posted In: BIMI
